LY367265, an inhibitor of the 5-hydroxytryptamine transporter and 5-hydroxytryptamine(2A) receptor antagonist: a comparison with the antidepressant, nefazodone (Q31494367)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	LY367265, an inhibitor of the 5-hydroxytryptamine transporter and 5-hydroxytryptamine(2A) receptor antagonist: a comparison with the antidepressant, nefazodone	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 July 2017

LY367265, an inhibitor of the 5-hydroxytryptamine transporter and 5-hydroxytryptamine(2A) receptor antagonist: a comparison with the antidepressant, nefazodone (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 July 2017

author name string

Pullar IA

1

1 reference

Europe PubMed Central

PubMed publication ID

2 July 2017

Carney SL

2

1 reference

Europe PubMed Central

PubMed publication ID

2 July 2017

Colvin EM

3

1 reference

Europe PubMed Central

PubMed publication ID

2 July 2017

Lucaites VL

4

1 reference

Europe PubMed Central

PubMed publication ID

2 July 2017

Nelson DL

5

1 reference

Europe PubMed Central

PubMed publication ID

2 July 2017

Wedley S

6

1 reference

Europe PubMed Central

PubMed publication ID

2 July 2017

language of work or name

0 references

publication date

1 October 2000

1 reference

Europe PubMed Central

PubMed publication ID

2 July 2017

European Journal of Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

2 July 2017

407

1 reference

Europe PubMed Central

PubMed publication ID

2 July 2017

1-2

1 reference

Europe PubMed Central

PubMed publication ID

2 July 2017

39-46

1 reference

Europe PubMed Central

PubMed publication ID

2 July 2017

The cortical serotonin2 receptors studied with positron-emission tomography and [18F]-setoperone during depressive illness and antidepressant treatment with clomipramine

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900728-7

7 January 2021

Effect of ritanserin on sleep stages and sleep EEG in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900728-7

7 January 2021

Sexual functioning in depressed outpatients taking mirtazapine

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900728-7

7 January 2021

Evidence for presynaptic location of inhibitory 5-HT1D beta-like autoreceptors in the guinea-pig brain cortex

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900728-7

7 January 2021

The effect of the selective 5-HT1A agonists alnespirone (S-20499) and 8-OH-DPAT on extracellular 5-hydroxytryptamine in different regions of rat brain

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900728-7

7 January 2021

Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900728-7

7 January 2021

Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900728-7

7 January 2021

5HT2 receptors, depression and anxiety

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900728-7

7 January 2021

Effects of seganserin, a 5-HT2 antagonist, and temazepam on human sleep stages and EEG power spectra

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900728-7

7 January 2021

Functional role of 5-HT2 receptors in the regulation of sleep and wakefulness in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900728-7

7 January 2021

omega-Agatoxin IVA identifies a single calcium channel subtype which contributes to the potassium-induced release of acetylcholine, 5-hydroxytryptamine, dopamine, gamma-aminobutyric acid and glutamate from rat brain slices

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900728-7

7 January 2021

5-HT uptake sites and 5-HT2 receptors in brain of antidepressant-free suicide victims/depressives: increase in 5-HT2 sites in cortex and amygdala

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900728-7

7 January 2021

5-Hydroxytryptamine-2 antagonist increases human slow wave sleep

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900728-7

7 January 2021

Clozapine acts as a 5-HT2 antagonist by attenuating DOI-induced inhibition of male rat sexual behaviour

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900728-7

7 January 2021

The use of mirtazapine in a group of 11 patients following poor compliance to selective serotonin reuptake inhibitor treatment due to sexual dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900728-7

7 January 2021

Serotonin-2 receptors and human sleep: effect of a selective antagonist on EEG power spectra.

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900728-7

7 January 2021

Brain 5-HT2 receptors in suicide victims: violence of death, depression and effects of antidepressant treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900728-7

7 January 2021

Pharmacological diversity between native human 5-HT1B and 5-HT1D receptors sited on different neurons and involved in different functions

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900728-7

7 January 2021

5-HT reuptake inhibitors with 5-HT(1B/1D) antagonistic activity: a new approach toward efficient antidepressants

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900728-7

7 January 2021

SB-236057, a selective 5-HT1B receptor inverse agonist, blocks the 5-HT human terminal autoreceptor

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900728-7

7 January 2021

Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900728-7

7 January 2021

Nefazodone and imipramine in major depression: a placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900728-7

7 January 2021

Combined administration of a 5-hydroxytryptamine (5-HT)1D antagonist and a 5-HT reuptake inhibitor synergistically increases 5-HT release in guinea pig hypothalamus in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900728-7

7 January 2021

Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900728-7

7 January 2021

DOI-induced inhibition of copulatory behavior in male rats: Reversal by 5-HT2 antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900728-7

7 January 2021

Decrease in brain serotonin 2 receptor binding in patients with major depression following desipramine treatment: a positron emission tomography study with fluorine-18-labeled setoperone

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900728-7

7 January 2021

Identifiers

10.1016/S0014-2999(00)00728-7

1 reference

Europe PubMed Central

PubMed publication ID

2 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q31494367&oldid=1543622760"